Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

This week, the Trump administration followed through on its planned mass layoffs at agencies under the US Department of ...

Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Dementia affects millions of people worldwide, causing a serious impact on the economy and the healthcare system. Alzheimer’s ...